Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biological medicine helps more people with rheumatoid arthritis

13.06.2008
Patients who have recently developed rheumatoid arthritis respond better to treatment with biological medicine in combination with conventional pharmacological medicine.

This according to results of the Swefot national clinical study, which is to be presented at an international rheumatology congress in Paris by scientists from Swedish Karolinska Institutet and Karolinska University Hospital, who conducted the study in association with another 15 rheumatology units in Sweden.

Some 60,000 people in Sweden have rheumatoid arthritis, and another 1,500 develop the disease every year. The symptoms are swollen, tender joints and impaired mobility. Some patients respond poorly to medical treatment and/or develop side effects. The Swefot study, which was launched in 2002, shows that a certain combination of pharmacological medicines and new biological medicines is more efficacious on these patients.

“After the disease has been confirmed in a patient, we start by treating it with Methotrexate, MTX,” says Ronald van Vollenhoven, Associate Professor and Senior Physician, and member of the study’s steering committee. “But for the group of patients who don’t respond well to MTX, it’s more effective to add a biological medicine than to combine MTX with an older drug.”

Biological medicines are a new group of drugs that have been in use for ten years and that are produced using modern DNA-based methods. What makes them special is that they can be designed to target a specific goal, which makes them more efficacious and reduces the risk of adverse reaction. They can only be injected and are complicated to produce, which means that the cost of a drug for one patient can exceed 100,000 kronor a year.

“Biological medicines have revolutionised rheumatologic therapy, but there are still some concerns, as the long-term effects are not fully known, and these medications are very expensive”, says Dr van Vollenhoven. “The Swefot trial is the first study in which the addition of biological treatment is compared directly to the addition of conventional antirheumatic medications.”

The study involved 487 patients, who had developed rheumatoid arthritis in the previous year. First they were treated with the most established anti-rheumatic medicine Methotrexate (MTX); after three or four months, the 258 patients who did not respond well to MTX were divided randomly into two treatment groups. Group A received a combination treatment with MTX, Sulfasalazin, and Plaquenil, three proven anti-rheumatic drugs. Group B received treatment with MTX and anti-TNF or Remicade (Infliximab), one of the most widely used biological drugs.

The analysis showed after twelve months that 26 per cent of the patients in Group A and 42 per cent of the patients in Group B responded well to the therapy. The difference was highly statistically significant and has been corroborated by several other analyses that also suggest the better efficacy of treatment strategy B. For the patients, a good response to the medicines means less pain and stiffness, better general wellbeing, improved function and a better quality of life.

Reference: The results of the study are to be presented on 12 June 2008 at an international rheumatism congress in Paris organised by the European League Against Rheumatism (EULAR). See the abstract for details of participating hospitals and scientists.

Katarina Sternudd | alfa
Further information:
http://www.karolinska.se

More articles from Health and Medicine:

nachricht Discovery shows promise for treating Huntington's Disease
05.08.2020 | Ecole Polytechnique Fédérale de Lausanne

nachricht Carbon monoxide improves endurance performance
05.08.2020 | Universität Bayreuth

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: ScanCut project completed: laser cutting enables more intricate plug connector designs

Scientists at the Fraunhofer Institute for Laser Technology ILT have come up with a striking new addition to contact stamping technologies in the ERDF research project ScanCut. In collaboration with industry partners from North Rhine-Westphalia, the Aachen-based team of researchers developed a hybrid manufacturing process for the laser cutting of thin-walled metal strips. This new process makes it possible to fabricate even the tiniest details of contact parts in an eco-friendly, high-precision and efficient manner.

Plug connectors are tiny and, at first glance, unremarkable – yet modern vehicles would be unable to function without them. Several thousand plug connectors...

Im Focus: New Strategy Against Osteoporosis

An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women...

Im Focus: AI & single-cell genomics

New software predicts cell fate

Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...

Im Focus: TU Graz Researchers synthesize nanoparticles tailored for special applications

“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.

Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...

Im Focus: Tailored light inspired by nature

An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.

Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“Conference on Laser Polishing – LaP 2020”: The final touches for surfaces

23.07.2020 | Event News

Conference radar for cybersecurity

21.07.2020 | Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

 
Latest News

Rare Earth Elements in Norwegian Fjords?

06.08.2020 | Earth Sciences

Anode material for safe batteries with a long cycle life

06.08.2020 | Power and Electrical Engineering

Turning carbon dioxide into liquid fuel

06.08.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>